Home Enzyme Replacement Therapy in Gaucher Disease: A Review

被引:0
|
作者
Kiec-Wilk, Beata [1 ,2 ]
Guijt, Paul [3 ]
Dan, Michaela [4 ]
Abdelwahab, Magy [5 ]
Revel-Vilk, Shoshana [6 ,7 ]
Serratrice, Christine [8 ,9 ]
机构
[1] Jagiellonian Univ, Med Coll, Dept Pathophysiol, Unit Rare Metab Dis, PL-31121 Krakow, Poland
[2] St John Paul II Specialist Hosp, Metab Dis Clin, PL-31202 Krakow, Poland
[3] Int Gaucher Alliance, London EC2A 4NE, England
[4] Romanian Gaucher Assoc, Cluj Napoca 400540, Romania
[5] Cairo Univ, Kasr ELainy Hosp, Pediat Hematol & BMT Dept & Gaucher Dis Clin, Pediat Hosp, Cairo 11562, Egypt
[6] Shaare Zedek Med Ctr, Gaucher Unit, Eisenberg R&D Author, IL-9103102 Jerusalem, Israel
[7] Hebrew Univ Jerusalem, Fac Med, IL-9103102 Jerusalem, Israel
[8] Univ Hosp Geneva, Div Internal Med Aged, CH-1256 Geneva, Switzerland
[9] Univ Geneva, Sch Med, CH-1206 Geneva, Switzerland
关键词
Gaucher disease; home therapy; enzyme replacement therapy; safety; compliance; MUCOPOLYSACCHARIDOSIS TYPE-I; LYSOSOMAL STORAGE DISORDERS; VELAGLUCERASE ALPHA; ADULT PATIENTS; FABRY-DISEASE; TYPE-1; SAFETY; INFUSION; IMIGLUCERASE; IMPACT;
D O I
10.3390/jcm14030842
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the early 1990s, Gaucher Disease has been a pioneering condition for home-based enzyme replacement therapy (ERT), marking a significant shift in patient care. Since then, many countries have adopted this approach. However, home ERT is not possible in all countries. Objectives: The aim of this article is to explore the implementation of home ERT for Gaucher disease, focusing on patient expectations, safety, compliance, economic benefits, and practical considerations. Methods: The PRISMA reporting protocol was followed, focusing on articles about home ERT for Gaucher Disease. Results: Twenty articles were analyzed in the review, revealing promising outcomes. Home ERT has consistently been shown to be safe, to improve patients' quality of life, to reduce the utilization of hospital resources, and to pose no compliance issues. Conclusions: We believe it is essential to expand the availability of home ERT for Gaucher Disease to all countries where ERT is accessible. Based on the literature review, we present the conditions that must be met before starting home ERT programs.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Enzyme replacement therapy for Gaucher disease
    Charrow, Joel
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (01) : 121 - 131
  • [2] ENZYME REPLACEMENT THERAPY FOR GAUCHER DISEASE
    BEUTLER, E
    KAY, A
    SAVEN, A
    GARVER, P
    THURSTON, D
    DAWSON, A
    ROSENBLOOM, B
    BLOOD, 1991, 78 (05) : 1183 - 1189
  • [3] Enzyme replacement therapy in type 1 Gaucher disease and a review of the literature
    Kabacam, Gokhan
    Kabacam, Gulsah
    Topcuoglu, Pervin
    Kuzu, Isinsu
    Arat, Mutlu
    TURKISH JOURNAL OF HEMATOLOGY, 2010, 27 (03) : 190 - 195
  • [4] Enzyme replacement therapy for Gaucher disease in Australia
    Goldblatt, J
    Szer, J
    Fletcher, JM
    McGill, J
    Rowell, JA
    Wilson, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (03) : 156 - 161
  • [5] Interruption of enzyme replacement therapy in Gaucher disease
    Goldblatt, J.
    Fletcher, J. M.
    McGill, J.
    Szer, J.
    Wilson, M.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2016, 106 (06): : S79 - S81
  • [6] Cessation of enzyme replacement therapy in Gaucher disease
    Grinzaid, KA
    Geller, E
    Hanna, SL
    Elsas, LJ
    GENETICS IN MEDICINE, 2002, 4 (06) : 427 - 433
  • [7] Interruption in enzyme replacement therapy for Gaucher disease
    Weinreb, NJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) : 1087 - 1088
  • [8] GAUCHER DISEASE - EFFICACY OF ENZYME REPLACEMENT THERAPY
    FALLET, S
    GRABOWSKI, GA
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 113 - 113
  • [9] ENZYME REPLACEMENT THERAPY OF INFANTILE GAUCHER DISEASE
    ERIKSON, A
    JOHANSSON, K
    MANSSON, JE
    SVENNERHOLM, L
    NEUROPEDIATRICS, 1993, 24 (04) : 237 - 238
  • [10] Enzyme replacement therapy for Gaucher's disease
    Beutler, E
    BAILLIERES CLINICAL HAEMATOLOGY, 1997, 10 (04): : 751 - 763